Exane Derivatives’s NewtekOne NEWT Stock Holding History

Exane Derivatives’s Portfolio NEWT Stock Details NEWT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$16.5K	Hold	870	–	–	0.01%	370
2022 Q1	$23.2K	Buy	+870	New	+$23.5K	0.01%	650

Other funds holding NEWT

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return

CRC

Curi RMB Capital Chicago, Illinois $6.48B AUM 30.25% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Exane Derivatives's NEWT Position: Q2 2022 in Review

Exane Derivatives held its NewtekOne (NEWT) position steady in Q2 2022 at 870 shares worth $16.5K. The position accounts for 0.01% of the portfolio, ranked #370.

Exane Derivatives first reported a position in NEWT in Q1 2022 and has held it in 2 quarters since. The position peaked at $23.2K in Q1 2022. 80 funds tracked by Wall St. Rank hold NEWT as of Q2 2022.

Exane Derivatives held 870 shares of NewtekOne worth $16.5K as of Q2 2022.
Exane Derivatives left its NewtekOne share count unchanged in Q2 2022.
NewtekOne made up 0.01% of Exane Derivatives's portfolio in Q2 2022, its #370 holding.
Exane Derivatives first reported a position in NewtekOne in Q1 2022 and has held it in 2 quarters since.
Exane Derivatives's NewtekOne position peaked at $23.2K in Q1 2022.
80 funds tracked by Wall St. Rank held NewtekOne as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.